AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19292211 — intervention group
Group type: COMPARATOR
Intervention: Bilateral total hip arthroplasty (THA)
Number of subjects: 50
Study 16243460 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment with 0.30% retinol for 21 days
Number of subjects: 14
Study 16243460 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment with 0.55% retinyl palmitate for 21 days
Number of subjects: 14
Study 16243460 — intervention group
Group type: COMPARATOR
Intervention: Single oral doses of 10,000 IU retinyl palmitate
Number of subjects: 14
Study 16243460 — intervention group
Group type: COMPARATOR
Intervention: Single oral doses of 30,000 IU retinyl palmitate
Number of subjects: 14
Study 12827681 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative radiation therapy (RT) at 50 Gy in daily fractions of 2 Gy, 5 days/week for 5 weeks
Number of subjects: 218
Study 12827681 — intervention group
Group type: COMPARATOR
Intervention: Sequential postoperative RT plus chemotherapy (CT) with 5-FU (450 mg/sqm/day i.v. bolus, days 1-5) and LEV (150 mg/day orally, days 1-3)
Number of subjects: 218
Study 12827681 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative radiation therapy (RT) alone
Number of subjects: 218
Study 12827681 — intervention group
Group type: COMPARATOR
Intervention: Sequential postoperative RT and CT
Number of subjects: 218
Study 11018607 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment arm (nifedipine XL, prednisone, trimethoprim/sulfa, plain acetaminophen)
Number of subjects: 70
Study 11018607 — intervention group
Group type: COMPARATOR
Intervention: Control arm (ketorolac, oxycodone, acetaminophen, prochlorperazine)
Number of subjects: 70
Study 8898770 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based heart disease prevention programs
Number of subjects: 1396
Study 8898770 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 1396
Study 8898770 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1396
Study 1501619 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrot-rice based rehydration solution (Na 57 mmol/L)
Number of subjects: 178
Study 1501619 — intervention group
Group type: COMPARATOR
Intervention: High-Na glucose electrolyte solution (Na 90 mmol/L)
Number of subjects: 178
Study 1501619 — intervention group
Group type: COMPARATOR
Intervention: Low-Na glucose electrolyte solution (Na 55 mmol/L)
Number of subjects: 178
Study 6371575 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotropic drug (3 X 200 mg EMD 21657)
Number of subjects: 100
Study 6371575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30821053 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg every 2 weeks (Q2W)
Number of subjects: 981
Study 30821053 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg monthly (QM)
Number of subjects: 981
Study 30821053 — intervention group
Group type: COMPARATOR
Intervention: Placebo Q2W
Number of subjects: 981
Study 30821053 — intervention group
Group type: COMPARATOR
Intervention: Placebo QM
Number of subjects: 981
Study 30821053 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (both dosing regimens)
Number of subjects: 981
Study 30821053 — intervention group
Group type: COMPARATOR
Intervention: Evolocumab and Placebo
Number of subjects: 981
Study 27614630 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth disinfection (FMD)
Number of subjects: 30
Study 27614630 — intervention group
Group type: COMPARATOR
Intervention: Quadrant scaling (QS)
Number of subjects: 30
Study 25723580 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-stemmed prosthesis
Number of subjects: 100
Study 25723580 — intervention group
Group type: COMPARATOR
Intervention: Conventional hip replacement
Number of subjects: 100
Study 24090993 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep massage therapy to posterior calf muscles and neural mobilization with self-stretch exercise program (DMS)
Number of subjects: 69
Study 23045537 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation
Number of subjects: 993
Study 23045537 — intervention group
Group type: COMPARATOR
Intervention: No navigation (control)
Number of subjects: 993
Study 19216776 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 21
Study 19216776 — intervention group
Group type: EXPERIMENTAL
Intervention: Truview laryngoscope
Number of subjects: 21
Study 19216776 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 21
Study 17241150 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (sympathomimetic)
Number of subjects: 50
Study 17241150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15042502 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask (PS-LMA)
Number of subjects: 104
Study 15042502 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal intubation (ET)
Number of subjects: 104
Study 11777715 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin sodium (10 IU/mL) in irrigation solution
Number of subjects: 50
Study 11777715 — intervention group
Group type: COMPARATOR
Intervention: Standard irrigating solution without heparin sodium
Number of subjects: 50
Study 11739983 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin users (509 patients)
Number of subjects: 1275
Study 11739983 — intervention group
Group type: COMPARATOR
Intervention: Nonusers (766 patients)
Number of subjects: 1275
Study 11739983 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin users and Nonusers
Number of subjects: 1275
Study 9406835 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-blocker (terazosin) 2 mg/d for 6 months
Number of subjects: 30
Study 9406835 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet for 6 months
Number of subjects: 30
Study 9406835 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-blocker (terazosin)
Number of subjects: 30
Study 8500302 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone or intravenous methylprednisolone followed by oral prednisone
Number of subjects: 457
Study 8500302 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 457
Study 3553200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (14 patients)
Number of subjects: 27
Study 3553200 — intervention group
Group type: COMPARATOR
Intervention: Aminoglycoside (13 patients)
Number of subjects: 27
Study 29705468 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS plus therapeutic ultrasound
Number of subjects: 64
Study 29705468 — intervention group
Group type: COMPARATOR
Intervention: Control CNP group (discouraged from using analgesics, allowed paracetamol)
Number of subjects: 64
Study 27717552 — intervention group
Group type: EXPERIMENTAL
Intervention: NPC‐01 (0.02 mg ethinyl estradiol and 1 mg norethisterone)
Number of subjects: 215
Study 27717552 — intervention group
Group type: EXPERIMENTAL
Intervention: IKH‐01 (0.035 mg ethinyl estradiol and 1 mg norethisterone)
Number of subjects: 215
Study 27717552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 27717552 — intervention group
Group type: EXPERIMENTAL
Intervention: NPC‐01
Number of subjects: 215
Study 25325894 — intervention group
Group type: EXPERIMENTAL
Intervention: High aspiration flow rate (40 cc/min; bottle height: 110 cm; vacuum: 400 mm Hg)
Number of subjects: 80
Study 25325894 — intervention group
Group type: COMPARATOR
Intervention: Low aspiration flow rate (20 cc/min; bottle height: 90 cm; vacuum: 400 mm Hg)
Number of subjects: 80
Study 25325894 — intervention group
Group type: EXPERIMENTAL
Intervention: High aspiration flow rate
Number of subjects: 80
Study 25325894 — intervention group
Group type: COMPARATOR
Intervention: Low aspiration flow rate
Number of subjects: 80
Study 20815129 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Nutrition Therapy Program (dietary strategies)
Number of subjects: 69
Study 20815129 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire measuring adherence (0-100%)
Number of subjects: 69
Study 20815129 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perception of adherence (0-100%)
Number of subjects: 69
Study 20815129 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic control (capillary glucose self-monitoring)
Number of subjects: 69
Study 18268073 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-daily BIAsp 30
Number of subjects: 321
Study 18268073 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily BIAsp 30
Number of subjects: 321
Study 18268073 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 321
Study 15741434 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (800 microg/day)
Number of subjects: 60
Study 15741434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 14506118 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged antithrombotic pretreatment (3 to 5 days)
Number of subjects: 410
Study 14506118 — intervention group
Group type: COMPARATOR
Intervention: Early intervention (less than 6 hours after pretreatment)
Number of subjects: 410
Study 10382879 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (200 mg or 400 mg/day for 7 days)
Number of subjects: 32
Study 10382879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 10382879 — intervention group
Group type: COMPARATOR
Intervention: Lomefloxacin (400 mg/day for 7 days)
Number of subjects: 32
Study 9279672 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 0.1%
Number of subjects: 51
Study 9279672 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen 0.03%
Number of subjects: 51
Study 1948834 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestrogen therapy (Estraderm)
Number of subjects: 22
Study 29040773 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgery
Number of subjects: 105
Study 29040773 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma Knife Radiosurgery (GKS)
Number of subjects: 105
Study 27215836 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 43
Study 27215836 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 43
Study 25159343 — intervention group
Group type: COMPARATOR
Intervention: Didactic slide‐based lectures (SBL)
Number of subjects: 40
Study 25159343 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh tissue cadaver‐based training (CBT)
Number of subjects: 40
Study 25159343 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SBL and CBT
Number of subjects: 40
Study 22718840 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 107
Study 20457948 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV-C (Gamunex)
Number of subjects: 117
Study 20457948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 18368950 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of cefadroxil (500 mg)
Number of subjects: 24
Study 18368950 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of cefadroxil (500 mg)
Number of subjects: 24
Study 16572062 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (given twice daily during antibiotic therapy)
Number of subjects: 151
Study 16572062 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 151
Study 16572062 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 151
Study 16572062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 12658070 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.15 mg/70 kg, i.m.)
Number of subjects: 0
Study 12658070 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 0
Study 12658070 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 12658070 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone in combination with Clonidine
Number of subjects: 0
Study 12658070 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Drug B)
Number of subjects: 0
Study 10893848 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk group with baseline FG/I ratio and IL 2-h PG within the lower and upper quartile, respectively.
Number of subjects: 96
Study 10893848 — intervention group
Group type: COMPARATOR
Intervention: Control group with baseline FG/I ratio and IL 2-h PG within the second and third quartiles, respectively.
Number of subjects: 96
Study 9108813 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20-40 mg/day
Number of subjects: 1002
Study 9108813 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine 75-150 mg/day
Number of subjects: 1002
Study 8475955 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of aspirin from randomization to delivery
Number of subjects: 600
Study 8475955 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment from randomization to delivery
Number of subjects: 600
Study 8475955 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of aspirin
Number of subjects: 600
Study 8475955 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 600
Study 2435661 — intervention group
Group type: EXPERIMENTAL
Intervention: biofiltration‐PAN system
Number of subjects: 12
Study 2435661 — intervention group
Group type: COMPARATOR
Intervention: acetate-cuprophan hemodialysis
Number of subjects: 12
Study 31433347 — intervention group
Group type: EXPERIMENTAL
Intervention: KET/DEX (0.3 mg/kg bolus followed by 0.15 mg/kg/h infusion of ketamine + 0.7 μg/kg/h infusion of dexmedetomidine for 1.5 hours)
Number of subjects: 39
Study 31433347 — intervention group
Group type: COMPARATOR
Intervention: KET/FENT (0.3 mg/kg bolus followed by 0.15 mg/kg/h infusion of ketamine + three 25 μg fentanyl injections for 1.5 hours)
Number of subjects: 39
Study 31433347 — intervention group
Group type: EXPERIMENTAL
Intervention: KET/DEX
Number of subjects: 39
Study 30179953 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone and lidocaine
Number of subjects: 106
Study 30179953 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine alone (placebo)
Number of subjects: 106
Study 27177588 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based cardiovascular risk management (CVRM)
Number of subjects: 1671
Study 27177588 — intervention group
Group type: EXPERIMENTAL
Intervention: Training practice status
Number of subjects: 1671
Study 27177588 — intervention group
Group type: COMPARATOR
Intervention: Nurse involvement in CVRM tasks
Number of subjects: 1671
Study 27177588 — intervention group
Group type: COMPARATOR
Intervention: Practice size
Number of subjects: 1671
Study 25193529 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic retinopathy (none, mild nonproliferative, moderate/severe)
Number of subjects: 1862
Study 21993914 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency kyphoplasty (RFK)
Number of subjects: 114
Study 21993914 — intervention group
Group type: COMPARATOR
Intervention: Balloon kyphoplasty (BKP)
Number of subjects: 114
Study 19861358 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemisync sounds
Number of subjects: 60
Study 19861358 — intervention group
Group type: COMPARATOR
Intervention: Music
Number of subjects: 60
Study 19861358 — intervention group
Group type: COMPARATOR
Intervention: Blank cassette tape (control)
Number of subjects: 60
Study 18277064 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 16
Study 18277064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15711829 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine treatment (Interleukin-2 and/or interferon)
Number of subjects: 782
Study 12438678 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural or synthetic surfactant
Number of subjects: 50
Study 11019951 — intervention group
Group type: EXPERIMENTAL
Intervention: Frameless IUD
Number of subjects: 200
Study 11019951 — intervention group
Group type: COMPARATOR
Intervention: TCu380A
Number of subjects: 200
Study 11019951 — intervention group
Group type: EXPERIMENTAL
Intervention: Frameless IUD and TCu380A
Number of subjects: 200
Study 7547781 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser drainage (ALD)
Number of subjects: 93
Study 7547781 — intervention group
Group type: COMPARATOR
Intervention: Suture needle drainage (SND)
Number of subjects: 93
Study 7547781 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 93
Study 2185340 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy plus standard therapy followed by maintenance cisplatin for 6 months
Number of subjects: 462
Study 2185340 — intervention group
Group type: COMPARATOR
Intervention: Standard surgery and radiation
Number of subjects: 462
Study 2185340 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy (cisplatin and bleomycin) plus standard therapy
Number of subjects: 462
Study 7000121 — intervention group
Group type: EXPERIMENTAL
Intervention: Preirradiation with 25 Gy of 42 MeV X‐rays
Number of subjects: 14
Study 7000121 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment (unirradiated)
Number of subjects: 14
Study 30561061 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased perceived stress
Number of subjects: 90
Study 30561061 — intervention group
Group type: EXPERIMENTAL
Intervention: Externalization coping and self-efficacy
Number of subjects: 90
Study 28333533 — intervention group
Group type: EXPERIMENTAL
Intervention: BCT + IBT
Number of subjects: 61
Study 28333533 — intervention group
Group type: COMPARATOR
Intervention: IBT
Number of subjects: 61
Study 25375276 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotora-delivered intervention with 11 home visits and 4 telephone calls, including a 12-minute episode of a situation comedy and a family workbook.
Number of subjects: 361
Study 25375276 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotora-delivered intervention
Number of subjects: 361
Study 23565578 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flex posterior-stabilized (PS) TKA
Number of subjects: 36
Study 23565578 — intervention group
Group type: COMPARATOR
Intervention: Standard cruciate-retaining (CR) TKA
Number of subjects: 36
Study 21034839 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of normal saline injected into the knee joint cavity under ultrasonographic guidance
Number of subjects: 40
Study 21034839 — intervention group
Group type: COMPARATOR
Intervention: No joint infusion (control group)
Number of subjects: 40
Study 19384186 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 0
Study 19384186 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin inhibitor (CNI)
Number of subjects: 0
Study 17287897 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine, 20 mg/day
Number of subjects: 112
Study 17287897 — intervention group
Group type: COMPARATOR
Intervention: Rebamipide, 300 mg/day
Number of subjects: 112
Study 17287897 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 112
Study 12812865 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV subjects
Number of subjects: 22
Study 12812865 — intervention group
Group type: COMPARATOR
Intervention: Non-abused controls
Number of subjects: 22
Study 10767563 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation A - sodium chloride (0.9%) at pH 7.2
Number of subjects: 12
Study 10767563 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation B - sodium chloride (0.9%) at pH 5.8
Number of subjects: 12
Study 10767563 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation C - Sorensens phosphate buffer (0.06 M) at pH 5.8
Number of subjects: 12
Study 10767563 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation D - Sorensens phosphate buffer (0.13 M) at pH 5.8
Number of subjects: 12
Study 10767563 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation E - Sorensens phosphate buffer (0.06 M) adjusted to pH 5.0
Number of subjects: 12
Study 10767563 — intervention group
Group type: COMPARATOR
Intervention: All formulations (A to E)
Number of subjects: 12
Study 8815751 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 91
Study 8815751 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin + Nicotinic Acid (1.5 g)
Number of subjects: 91
Study 8815751 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin + Nicotinic Acid (2.25 to 3 g)
Number of subjects: 91
Study 8815751 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 91
Study 8815751 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 91
Study 8815751 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Pravastatin + Nicotinic Acid)
Number of subjects: 91
Study 8815751 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results
Number of subjects: 91
Study 1319876 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750mg
Number of subjects: 12
Study 1319876 — intervention group
Group type: EXPERIMENTAL
Intervention: Temafloxacin 600mg
Number of subjects: 12
Study 1319876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3938085 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirohydantoin Sorbinil
Number of subjects: 0
Study 3938085 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldose reductase inhibitors
Number of subjects: 0
Study 31164290 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 83
Study 31164290 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 83
Study 31164290 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 83
Study 29440045 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus rescue medication (RM)
Number of subjects: 414
Study 29440045 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture plus RM
Number of subjects: 414
Study 29440045 — intervention group
Group type: COMPARATOR
Intervention: Rescue medication (RM) alone
Number of subjects: 414
Study 27449367 — intervention group
Group type: EXPERIMENTAL
Intervention: Triadic parent‐infant Relationship Therapy (TRT)
Number of subjects: 65
Study 27449367 — intervention group
Group type: COMPARATOR
Intervention: Control group (preterm infants)
Number of subjects: 65
Study 25433184 — intervention group
Group type: EXPERIMENTAL
Intervention: SCCT-based educational intervention combined with EBP CPE program (standard-plus group)
Number of subjects: 580